Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:

Leerink Partners 2025 Global Healthcare Conference
Tuesday, March 11, 2025

Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025

Barclays 27^th Annual Global Healthcare Conference
Thursday, March 13, 2025

About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM^®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:
Ian Karp
Head of Investor Relations
[email protected]

Danielle Jesse
Director, Investor Relations
[email protected]

Media Contact:
Cheryl Wheeler
Head of Corporate Communications
[email protected]

You May Also Be Interested In

• Cogent Communications Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cogent Communications Holdings, Inc.
• Best Meme Coin To Invest In: DOGE Whales Scoop $48M as AlphaPepe Targets the Earlier Next Shiba Inu Trade
• Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update